DE69534601D1 - Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien - Google Patents

Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien

Info

Publication number
DE69534601D1
DE69534601D1 DE69534601T DE69534601T DE69534601D1 DE 69534601 D1 DE69534601 D1 DE 69534601D1 DE 69534601 T DE69534601 T DE 69534601T DE 69534601 T DE69534601 T DE 69534601T DE 69534601 D1 DE69534601 D1 DE 69534601D1
Authority
DE
Germany
Prior art keywords
bacteria
myko
grampositive
antibodies
effects caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534601T
Other languages
English (en)
Other versions
DE69534601T2 (de
Inventor
J Ulevitch
S Tobias
Jerome Pugin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Application granted granted Critical
Publication of DE69534601D1 publication Critical patent/DE69534601D1/de
Publication of DE69534601T2 publication Critical patent/DE69534601T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
DE69534601T 1994-09-16 1995-09-15 Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien Expired - Lifetime DE69534601T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30793194A 1994-09-16 1994-09-16
US307931 1994-09-16
PCT/US1995/011770 WO1996008272A1 (en) 1994-09-16 1995-09-15 Use of antibodies to block the effects of gram-positive bacteria and mycobacteria

Publications (2)

Publication Number Publication Date
DE69534601D1 true DE69534601D1 (de) 2005-12-15
DE69534601T2 DE69534601T2 (de) 2006-08-03

Family

ID=23191790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534601T Expired - Lifetime DE69534601T2 (de) 1994-09-16 1995-09-15 Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien

Country Status (9)

Country Link
US (3) US6168790B1 (de)
EP (1) EP0792162B1 (de)
JP (1) JP3892902B2 (de)
AT (1) ATE308994T1 (de)
CA (1) CA2200054C (de)
DE (1) DE69534601T2 (de)
DK (1) DK0792162T3 (de)
ES (1) ES2255708T3 (de)
WO (1) WO1996008272A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766593A (en) * 1994-12-30 1998-06-16 Amgen Inc. Anti-inflammatory CD14 peptides
AU6392996A (en) * 1995-06-19 1997-01-15 Sanna M. Goyert A method for inhibiting bacteremia and bacterial dissemination
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO2000042994A2 (en) * 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
CA2383838A1 (en) * 1999-09-17 2001-03-29 Mochida Pharmaceutical Co., Ltd. Method of fractional measurement of soluble cd14 protein
WO2001072993A1 (fr) * 2000-03-31 2001-10-04 Mochida Pharmaceutical Co., Ltd. Inhibiteur de liaison entre le recepteur de type toll et cd14
JPWO2002042333A1 (ja) * 2000-11-22 2004-03-25 持田製薬株式会社 Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
AU2002362753B9 (en) * 2001-10-05 2008-05-15 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
CN1787741B (zh) 2003-05-15 2011-08-17 唐纳士公司 用于预防和治疗败血症的方法与组合物
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
KR20200015477A (ko) * 2017-04-21 2020-02-12 임플리싯 바이오사이언스 피티와이 엘티디 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis
EP0513242A1 (de) * 1990-02-01 1992-11-19 The Rockefeller University Lipopolysaccharid-bindendes opsonin und verfahren zu dessen benutzung
DE69434812D1 (de) * 1993-05-28 2006-09-14 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung

Also Published As

Publication number Publication date
AU703169B2 (en) 1999-03-18
US6168790B1 (en) 2001-01-02
EP0792162A1 (de) 1997-09-03
DE69534601T2 (de) 2006-08-03
JP3892902B2 (ja) 2007-03-14
CA2200054C (en) 2010-03-16
DK0792162T3 (da) 2006-03-27
US20010022969A1 (en) 2001-09-20
US20030103969A1 (en) 2003-06-05
CA2200054A1 (en) 1996-03-21
AU3633695A (en) 1996-03-29
JPH10505839A (ja) 1998-06-09
EP0792162B1 (de) 2005-11-09
ES2255708T3 (es) 2006-07-01
ATE308994T1 (de) 2005-11-15
WO1996008272A1 (en) 1996-03-21
EP0792162A4 (de) 2003-03-19

Similar Documents

Publication Publication Date Title
FI920450A0 (fi) Metoder och kompositioner foer foerhindrande av symtomer av sepsis.
ATE308994T1 (de) Gebrauch von antikörpern zur verhinderung von auswirkungen hervorgerufen durch grampositive- und myko-bakterien
ATE448792T1 (de) Verwendung von botulinumtoxin zur behandlung der renitenten blasenentleerungsstörung
DE69526340T2 (de) Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
DE69321909D1 (de) Verwendung von monoklonalen Anti-TNF-Antikörpern für die Behandlung von bakteriellen Meningitiden
RU2000105905A (ru) Способ лечения острого повреждения легких и способ лечения фиброза, моноклональное антитело, гибридома атсс нв12382
FI964845A (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
ATA29495A (de) Zusammensetzung und verfahren zur prävention und behandlung von entzündungen mit immunglobulin a
DE69434384D1 (de) Metalkomplexbildner
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
DE69213935T2 (de) Neue heterocyclische carbonsäuren
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
ATE136222T1 (de) Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren
Moroz et al. Neutralization of Vipera palestinae hemorrhagin by antibody fragments
FI924278A (fi) Bcrf1 antagonister foer skoetsel av epstein-barr-virusinfektioner

Legal Events

Date Code Title Description
8364 No opposition during term of opposition